Dose-dependent effect of parenteral iron therapy on bleomycin-detectable iron in immune apheresis patients.

Background: Iron deficiency and anemia are commonly encountered in patients with autoimmune diseases undergoing immune apheresis. This makes erythropoietin and iron substitution necessary in most patients. However, intravenous iron therapy may result in an increase of potentially toxic nontransferrin-bound iron.